Your browser doesn't support javascript.
loading
Duration of Bisphosphonate Treatment / 대한내과학회지
Korean Journal of Medicine ; : 151-155, 2014.
Article en Ko | WPRIM | ID: wpr-226803
Biblioteca responsable: WPRO
ABSTRACT
Large, randomized, controlled trials have demonstrated the efficacy of bisphosphonates (BP) in terms of improving bone mineral density (BMD) and reducing fracture risk. Consequently, bisphosphonates are used widely in the treatment of osteoporosis. Recently, however, several safety issues regarding the long-term use of BP, especially BP-related osteonecrosis of the jaws and atypical fractures, have been noted and have emerged as a limitation of their clinical use. Although the absolute risk is very small, the risks could increase with the long-term use of BP. The anti-fracture efficacy of BP is not sustained after treatment for 5-10 years. Therefore, recommendations suggest that a drug holiday be considered after 5 years of treatment for patients at low risk of fracture. However, as the individual fracture risk varies, the treatment duration should be based on individual clinical risk factors and bone metabolism status. Moreover, recommendations regarding monitoring after discontinuing and reinitiating BP await further studies.
Asunto(s)
Palabras clave
Texto completo: 1 Índice: WPRIM Asunto principal: Osteonecrosis / Osteoporosis / Densidad Ósea / Factores de Riesgo / Difosfonatos / Vacaciones y Feriados / Maxilares / Metabolismo Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Límite: Humans Idioma: Ko Revista: Korean Journal of Medicine Año: 2014 Tipo del documento: Article
Texto completo: 1 Índice: WPRIM Asunto principal: Osteonecrosis / Osteoporosis / Densidad Ósea / Factores de Riesgo / Difosfonatos / Vacaciones y Feriados / Maxilares / Metabolismo Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Límite: Humans Idioma: Ko Revista: Korean Journal of Medicine Año: 2014 Tipo del documento: Article